OR WAIT 15 SECS
The company made a €42 million investment in a new building at its Reinbek site to support the production of biopharmaceuticals.
On March 2, 2017, Merck KGaA, Darmstadt, Germany’s allergy business, Allergopharma, began biopharmaceutical production in Reinbek, near Hamburg, Germany. The company made a €42-million (approximately $44.4 million) investment in a new building at its Reinbek site to support the production of biopharmaceuticals.
‘‘By this €42-million investment our company is supporting the Reinbek site in order to expand the allergies business on a global scale. The new production building is part of this global expansion, and will support our growing business in the allergy market place,” said Simon Sturge, COO at the Healthcare business sector of Merck KGaA, Darmstadt, Germany, at the inauguration in Reinbek in a statement.
The new biopharmaceutical factory covers 6000 m2 and includes a glass cleanroom, in which the company will manufacture its products for causal treatment, on the 2000-m2 ground floor of the building. Alongside the cleanrooms for biopharmaceutical production, the new building has a glass visitors’ foyer with a view of the cleanrooms and the potential for extension to accommodate further filling lines. Merck KGaA, Darmstadt, Germany, laid the foundations for the building in December 2013.
Source: Merck KGaA, Darmstadt, Germany